SCYNEXIS (NASDAQ: SCYX) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare SCYNEXIS to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
30.9% of SCYNEXIS shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 4.0% of SCYNEXIS shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
SCYNEXIS has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, SCYNEXIS’s competitors have a beta of 37.68, indicating that their average stock price is 3,668% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for SCYNEXIS and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SCYNEXIS presently has a consensus target price of $9.50, suggesting a potential upside of 394.79%. As a group, “Pharmaceuticals” companies have a potential upside of 18.95%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, equities research analysts clearly believe SCYNEXIS is more favorable than its competitors.
This table compares SCYNEXIS and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares SCYNEXIS and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SCYNEXIS Competitors||$8.31 billion||$1.11 billion||144.46|
SCYNEXIS’s competitors have higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
SCYNEXIS competitors beat SCYNEXIS on 9 of the 13 factors compared.
SCYNEXIS Company Profile
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.